AtriCure logo

AtriCureNASDAQ: ATRC

Profile

Sector:

Healthcare

Country:

United States

IPO:

05 August 2005

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.59 B
-60%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-58%vs. 3y high
72%vs. sector
-77%vs. 3y high
51%vs. sector

Price

after hours | Thu, 31 Oct 2024 20:15:01 GMT
$32.54-$2.32(-6.66%)

Dividend

No data over the past 3 years
$115.91 M$119.85 M
$115.91 M-$7.85 M

Analysts recommendations

Institutional Ownership

ATRC Latest News

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
seekingalpha.com29 October 2024 Sentiment: NEUTRAL

AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.

AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com29 October 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
zacks.com29 October 2024 Sentiment: POSITIVE

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.

AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
zacks.com16 October 2024 Sentiment: POSITIVE

ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.

AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
zacks.com11 October 2024 Sentiment: POSITIVE

ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
zacks.com28 August 2024 Sentiment: POSITIVE

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
zacks.com23 August 2024 Sentiment: POSITIVE

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
seekingalpha.com31 July 2024 Sentiment: NEUTRAL

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com30 July 2024 Sentiment: POSITIVE

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AtriCure (ATRC) Gains China Approval for AtriClip LAA System
zacks.com24 July 2024 Sentiment: POSITIVE

AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.

  • 1(current)

What type of business is AtriCure?

AtriCure, Inc. is a large healthcare system company that specializes in the development, manufacturing, and sale of equipment and systems for physicians working in the field of cardiothoracic surgery in the United States and abroad. The company was founded in 2000 and is based in Mason, Ohio. The company's portfolio includes 3 categories of products: Products for open and minimally invasive ablation include a range of Synergy Isolator clamps for the treatment of persistent atrial fibrillation. The company's products for open ablation include the CryoICE cryoablation system. Products for minimally invasive ablation provide a coagulation system under EPi-Sense control with VisiTrax technology, using monopolar energy for tissue coagulation.

What sector is AtriCure in?

AtriCure is in the Healthcare sector

What industry is AtriCure in?

AtriCure is in the Medical Instruments & Supplies industry

What country is AtriCure from?

AtriCure is headquartered in United States

When did AtriCure go public?

AtriCure initial public offering (IPO) was on 05 August 2005

What is AtriCure website?

https://www.atricure.com

Is AtriCure in the S&P 500?

No, AtriCure is not included in the S&P 500 index

Is AtriCure in the NASDAQ 100?

No, AtriCure is not included in the NASDAQ 100 index

Is AtriCure in the Dow Jones?

No, AtriCure is not included in the Dow Jones index

When was AtriCure the previous earnings report?

No data

When does AtriCure earnings report?

Next earnings report date is not announced yet